• Markets
    • icon
  • Companies
EMV · ASX

EMvision Medical Devices Ltd. (ASX:EMV)

AU$1.99

 -0.04 (-1.97%)
ASX:Live
26/07/2024 04:10:15 PM
HALO Ords GROWTH AUS All-Companies
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

EMV Overview

EMV Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Strong

GARP

Very Strong

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Neutral

Earnings

Very Strong

Growth

Earnings

Very Strong

Dividends

Very Strong

Quality

Capital Efficiency

Very Strong

Balance Sheet

Very Strong

About EMV

Website

EMvision Medical Devices Ltd.

Telephone

61.2.8667.5337

Address

Suite 4.01 65 Epping Road Macquarie Park, New South Wales (NSW) 2113

Description

EMvision Medical Devices Ltd. engages in the development & commercialization of medical imaging technology. The company was founded on July 11, 2017, and is headquartered in Brisbane, Australia.

EMV Price Chart

Key Stats

Market Cap

AU$172.56M

PE

49.10

EV/EBITDA

0.0

Dividends Overview

DIV Yield

.0%

Franking

%

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 1.21 - 2.72

Trade Value (12mth)

AU$21,858.00

1 week

2.78%

1 month

-7.73%

YTD

-2.87%

1 year

67.77%

All time high

4.20

Key Fundamentals

EPS 3 yr Growth

-12.000%

EBITDA Margin

N/A

Operating Cashflow

$1m

Free Cash Flow Return

12.80%

ROIC

-59.30%

Interest Coverage

-300.10

Quick Ratio

1.70

Other Data

Shares on Issue (Fully Dilluted)

78m

HALO Sector

Healthcare

Next Company Report Date

27-Aug-24

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.00

EMV Announcements

Latest Announcements

Date Announcements

23 July 24

First Responder Device Unveiled

×

First Responder Device Unveiled

08 July 24

Stage 3 Recuitment Achieved & FDA Engagement Underway

×

Stage 3 Recuitment Achieved & FDA Engagement Underway

24 June 24

Pilot Production Line Established & $1.25m Grant Received

×

Pilot Production Line Established & $1.25m Grant Received

27 May 24

Trial data confirms early ischaemia detection capabilities

×

Trial data confirms early ischaemia detection capabilities

26 April 24

Notification of cessation of securities - EMV

×

Notification of cessation of securities - EMV

24 April 24

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

27 March 24

Stage 2 Insights Confirm Diagnostic & Clinical Viability

×

Stage 2 Insights Confirm Diagnostic & Clinical Viability

13 March 24

ASA Milestone Achieved for $0.6m Grant Payment

×

ASA Milestone Achieved for $0.6m Grant Payment

07 March 24

Board Changes

×

Board Changes

07 March 24

Final Director's Interest Notice

×

Final Director's Interest Notice

07 March 24

Initial Director's Interest Notice

×

Initial Director's Interest Notice

01 March 24

Application for quotation of securities - EMV

×

Application for quotation of securities - EMV

01 March 24

Application for quotation of securities - EMV

×

Application for quotation of securities - EMV

01 March 24

Notification of cessation of securities - EMV

×

Notification of cessation of securities - EMV

01 March 24

Cleansing Notice

×

Cleansing Notice

01 March 24

Becoming a substantial holder

×

Becoming a substantial holder

29 February 24

Strategic A$15.28M Investment from Keysight Technologies

×

Strategic A$15.28M Investment from Keysight Technologies

29 February 24

Proposed issue of securities - EMV

×

Proposed issue of securities - EMV

29 February 24

Half Yearly Report and Accounts

×

Half Yearly Report and Accounts

29 February 24

CEO Half Yearly Update

×

CEO Half Yearly Update

31 January 24

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

18 December 23

EMVision Receives $2.58m R&D Rebate & ASA Milestone Achieved

×

EMVision Receives $2.58m R&D Rebate & ASA Milestone Achieved

12 December 23

Notification of cessation of securities - EMV

×

Notification of cessation of securities - EMV

27 November 23

Stage 2 Trial Recruitment Tartget Reached & EMU Unveiled

×

Stage 2 Trial Recruitment Tartget Reached & EMU Unveiled

21 November 23

Amended Constitution

×

Amended Constitution

EMV Fundamentals

Per Share Records

Historical data

Forecast data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.12 -0.08 -0.05 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.12 -0.08 -0.05 Lock Lock Lock
     Growth % Lock Lock Lock Lock -111.7 32.2 38.7 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A 49.1 Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.06 -0.05 -0.02 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.07 -0.05 0.01 Lock Lock Lock
     Growth % Lock Lock Lock Lock -14.6 15.1 60.1 Lock Lock Lock
     Yield % Lock Lock Lock Lock -2.2 -3.5 0.7 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.14 0.09 0.07 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.13 0.09 0.06 Lock Lock Lock
     Growth % Lock Lock Lock Lock 68.0 -36.0 -30.0 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 70 75 78 Lock Lock Lock
Basic m Lock Lock Lock Lock 70 75 78 Lock Lock Lock

Financial Records

Historical data

Forecast data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Income Statement
Sales $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 10 10 11 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A -113.5 -40.5 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock N/A N/A 0 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -10 -10 -11 Lock Lock Lock
     Growth % Lock Lock Lock Lock -96.9 -1.5 -3.5 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -10 -10 -11 Lock Lock Lock
     Growth % Lock Lock Lock Lock -99.2 -2.8 -4.4 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -10 -8 -6 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock -1 -2 -3 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -8 -6 -4 Lock Lock Lock
     Growth % Lock Lock Lock Lock -141.6 27.3 36.6 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -4 -4 1 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 9 1 3 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -5 -4 1 Lock Lock Lock
     Growth % Lock Lock Lock Lock -42.0 14.0 116.3 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock N/A N/A 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 10 7 10 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 11 9 12 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 0 1 0 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -9 -6 -7 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 1 1 6 Lock Lock Lock
Equity $m Lock Lock Lock Lock 10 7 5 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 10 8 5 Lock Lock Lock
     Growth % Lock Lock Lock Lock 82.8 -24.5 -28.8 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -78.0 -71.8 -33.6 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -83.5 -86.3 -75.7 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -129.0 -115.7 -136.8 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -107.5 -69.0 -59.3 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -57.5 -42.7 12.8 Lock Lock Lock

Ratios Records

Historical data

Forecast data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Leverage
Interest Cover X Lock Lock Lock Lock -1,023.7 -564.2 -300.1 Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 0.9 0.6 0.7 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -94.3 -85.6 -135.4 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 14.8 8.3 1.7 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 14.8 8.3 1.7 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 97.1 96.2 97.4 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -664.7 -442.9 13.8 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -78.0 -71.8 -33.6 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.1 1.2 2.3 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -83.5 -86.3 -75.7 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -83.5 -86.3 -75.7 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 822.1 278.9 271.6 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock -822.1 -278.9 -271.6 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

.0%

Franking Level

%

DPSg

N/A

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

EMV Shortsell

Frequently Asked Questions

The current share price of EMvision Medical Devices Ltd. (EMV:ASX) is AU$1.99.
The 52-week high share price for EMvision Medical Devices Ltd. (EMV:ASX) is AU$2.72.
The 52-week low share price for EMvision Medical Devices Ltd. (EMV:ASX)? is AU$1.21.
The current TTM dividend payout for EMvision Medical Devices Ltd. (EMV:ASX) is 0.00.
EMvision Medical Devices Ltd. (EMV:ASX) does not pay a dividend.
EMvision Medical Devices Ltd. (EMV:ASX) does not offer franking credits.
EMvision Medical Devices Ltd. (EMV:ASX) is classified in the Healthcare.
The current P/E ratio for EMvision Medical Devices Ltd. (EMV:ASX) is 49.10.
logo
Login
Company
Company
Important

Get the latest insights and hot tips delivered right to your inbox

App Store Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.